Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLIPPER Study
2015-002437-21Phase 2Active
- Sponsor
- GEICAM
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing Faslodex + Palbociclib with Faslodex + placebo (2 arms). Primary endpoint: Rate of patients free of progression at 1 year. Started Sep 2015; status: active.
02
Drugs
fulvestrantpalbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2015-002437-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002437-21.